Social Media to Congress: “Piss Off!”
I love a Congressional investigation as well as the next guy, especially when it involves purported wrong-doing by pharmaceutical company bigwigs.The House Committee on...
Jarvik Can’t Prescribe and Can’t Row a Boat, But Can He Sell?
"He can't row," said Dr. O. H. Frazier of the Texas Heart Institute of Dr. Jarvik, Pfizer's Lipitor celebrity spokesperson. And Dr. Frazier should...
Making Fun of Pharma Marketing is Easy
I've just returned from a few days vacation on the beach in Sunny Isles, Florida and I haven't yet recovered from the Motivational Deficiency...
What’s Your Social Media Readiness Score?
Sometimes, pharmaceutical marketers must feel like they are doomed if they do or if they don't engage in new media marketing such as "social...
4th Annual Summit on Post-Marketing Studies
Design Post-Approval Studies for Improved Safety and Risk Assessment while Meeting Clinical, Marketing and Regulatory Objectives
Prescription Drugs and the Health 2.0 Opportunity
A review of some of the features of the eDrugSearch.com Community -- a new Health 2.0 Web site.
Understanding the Strategic Value of MSLs
This article examines how tomorrow's MSL might be employed by Pharma and discusses the strategic movement of MSLs into the competitive intelligence space, teaching roles, strategic input to and evaluation of portfolio development, and investor relations.
Helping Pharma eMarketing “Grow Up”
This article summarizes a Pharma Marketing Talk conversation with Carolina Petrini, SVP, Marketing Solutions, comScore, regarding her company's consumer e-marketing effectiveness benchmarks for the pharmaceutical industry.
FDA’s Good Reprint Practices Guidance
Medical journals may soon become the pharmaceutical industry's newest physician marketing partner. This article summarizes some of the pros and cons of FDA's Good Reprint Practices Guidance and presents preliminary results of a reader survey on the topic.
FDA’s Good Reprint Practices Guidance
Medical journals may soon become the pharmaceutical industry's newest physician marketing partner. This article summarizes some of the pros and cons of FDA's Good Reprint Practices Guidance and presents preliminary results of a reader survey on the topic.
